Within this framework, erythropoietin (EPO) and its analogs have gained renewed interest not only in treating anemia but also in a variety of non-hematologic conditions, including neurodegeneration, metabolic dysfunctions, and ischemic injuries [28]. Here, EPO is linked to anemia (phenotype).